Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn's disease cohort

Show full item record



Permalink

http://hdl.handle.net/10138/321983

Citation

af Björkesten , C-G , Ilus , T , Hallinen , T , Soini , E , Eberl , A , Hakala , K , Heikura , M , Jussila , A , Koskela , R , Koskinen , I , Moilanen , V , Nielsen , C , Nieminen , U , Nuutinen , H , Heikkinen , M , Suhonen , U-M , Tillonen , J , Utriainen , K , Vihriälä , I , Wennerström , C , Borsi , A , Nissinen , R , Koivunen , M R & Sipponen , T 2020 , ' Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn's disease cohort ' , European Journal of Gastroenterology and Hepatology , vol. 32 , no. 12 , pp. 1507-1513 . https://doi.org/10.1097/MEG.0000000000001831

Title: Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn's disease cohort
Author: af Björkesten, Clas-Göran; Ilus, Tuire; Hallinen, Taru; Soini, Erkki; Eberl, Anja; Hakala, Kalle; Heikura, Mikko; Jussila, Airi; Koskela, Ritva; Koskinen, Inka; Moilanen, Veikko; Nielsen, Christian; Nieminen, Urpo; Nuutinen, Heikki; Heikkinen, Markku; Suhonen, Ulla-Maija; Tillonen, Jyrki; Utriainen, Karri; Vihriälä, Ilkka; Wennerström, Christina; Borsi, Andras; Nissinen, Riikka; Koivunen, Minni R.; Sipponen, Taina
Contributor: University of Helsinki, HUS Abdominal Center
University of Helsinki, HUS Abdominal Center
University of Helsinki, HUS Abdominal Center
University of Helsinki, HYKS erva
University of Helsinki, HUS Abdominal Center
Date: 2020-12
Language: eng
Number of pages: 7
Belongs to series: European Journal of Gastroenterology and Hepatology
ISSN: 0954-691X
URI: http://hdl.handle.net/10138/321983
Abstract: Objective Long-term evidence on ustekinumab treatment response and persistence in patients with Crohn's disease in a real-world setting is scarce. We performed a retrospective nationwide chart review study of long-term clinical outcomes in Crohn's disease patients treated with ustekinumab. Methods The study was conducted in 17 Finnish hospitals and included adult Crohn's disease patients who received an initial intravenous dose of ustekinumab during 2017-2018. Disease activity data were collected at baseline, 16 weeks, and 1 year from health records. Results The study included 155 patients. The disease was stricturing or penetrating in 69 and 59% had prior Crohn's disease-related surgeries, and 97% had a treatment history of at least one biologic agent. Of 93 patients with >= 1 year of follow-up, 77 (83%) were still on ustekinumab at 1 year. In patients with data available, from baseline to the 1-year follow-up the simple endoscopic score for Crohn's disease (SES-CD) decreased from 10 to 3 (P = 0.033), C-reactive protein from 7 to 5 mg/L, (P 0.001) and faecal calprotectin from 776 to 305 mu g/g (P 0.001). Conclusions Ustekinumab treatment in patients with highly refractory Crohn's disease resulted in high long-term treatment persistence and significantly reduced disease activity, assessed with objective markers for intestinal inflammatory activity.
Subject: biologics
biomarkers
calprotectin
Crohn&#8217
s disease
endoscopic healing
inflammatory bowel disease
simple endoscopic score for Crohn&#8217
ustekinumab
MAINTENANCE THERAPY
INDUCTION
OUTCOMES
3121 General medicine, internal medicine and other clinical medicine
3111 Biomedicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Objectively_ass ... se_activity_and_drug.3.pdf 692.1Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record